University of Glasgow
Transcriptomic and glycobiological profiling of synovial fibroblasts in rheumatoid arthritis: the role of sialylation in fibroblast-macrophage crosstalk
Abstract
dc:description.abstractRheumatoid arthritis (RA) is a chronic autoimmune disease in which synovial fibroblasts (SFs) and macrophages perpetuate inflammation and tissue destruction. While immune cell directed therapies are effective, treatment resistance underscores the importance of stromal contributions. Glycosylation, particularly sialylation, has emerged as a key regulatory mechanism in stromal-immune crosstalk. Here, we investigated the role of sialylation in shaping SF function and macrophage responses. Bulk RNA sequencing of human RA synovia revealed TNF-α driven remodelling of glycosylation pathways, with upregulation of ST3GAL family members, indicating a pro–α2-3 bias in inflamed fibroblasts. Single-cell RNA-seq mapped these alterations to discrete fibroblast subsets and linked them to lectin receptor expression in tissue-resident macrophages, including Siglecs and Galectins. Using an in vitro desialylation model, we demonstrated that selective removal of α2-3 sialic acids reprogrammed SFs toward a pro-inflammatory phenotype, enhancing cytokine secretion. Conditioned media from these fibroblasts induced M1-like polarisation of bone marrow derived macrophages, with increased Il1b, Nos2, CD80/CD86, and pathway enrichment for TNF and NF-κB signalling, In contrast, broad α2-3/α2-6 cleavage elicited mixed macrophage responses, while less α2-3 linked sialic acid removal had minimal effects. Protein-level analyses confirmed increased PD-L1 in macrophages exposed to desialylated fibroblast supernatants. These findings identify stromal sialylation as a molecular checkpoint regulating joint inflammation. Loss of α2-3 sialylation above certain thresholds functions as a pro-inflammatory switch in SFs, amplifying macrophage activation and sustaining chronic inflammation. Targeting stromal glycosylation offers a potential therapeutic avenue and biomarker strategy in RA.
Degree
thesis:*- Level dc:type.qualificationlevel
- PhD
- Grantor dc:publisher.institution
- University of Glasgow
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Cil, Caglar
Subjects
dc:subject × 2Rights
- Language dc:language
- en
Identifiers
dc:identifier.*- DOI dc:identifier.doi
- https://doi.org/10.5525/gla.thesis.85712